No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
269 |
4. Check minimum number of eventsNone |
269 |
5. Include endpointsNone |
269 |
6. Filter based on genotype QC (FinnGen only) |
239 |
Control definitions (FinnGen only)
- Control exclude
- Q17_OTHER_CONGEN_MALFO
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Neurofibromatosis, type 1
based on the number of shared cases.
Similar with more cases:
- Phakomatoses, not elsewhere classified
- Other congenital malformations
- Other congenital malformations, including avohilmo
- Congenital malformations, deformations and chromosomal abnormalities
- Congenital malformations, deformations and chromosomal abnormalities, including avohilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 239 | 145 | 94 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | 37.30 | 36.96 | 37.83 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 253
- Matched controls
- 2530
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q85.00
ICD-10 Finland
Neurofibromatosis, type 1
+∞
307.7
253
*
Q85.09
ICD-10 Finland
Unspecified neurofibromatosis
+∞
151.8
130
*
Z31.5
ICD-10 Finland
Genetic counselling
21.7
125.2
114
92
Q85.0
ICD-10 Finland
Neurofibromatosis (nonmalignant)
+∞
97.3
87
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
15.8
78.0
77
68
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
12.4
54.1
60
62
2377A
ICD-9 Finland
Neoplasm of uncertain behaviour of endocrine glands and nervous system, Neurofibromatosis
+∞
53.0
49
*
Q85.01
ICD-10 Finland
Neurofibromatosis, type 2
+∞
48.5
45
*
QDE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in lower limb
16.7
46.1
41
29
74340
ICD-8 Finland
Other congenital anomalies of nervous system, Neurofibromatosis
+∞
38.5
36
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.6
37.0
72
143
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.1
33.9
99
281
XCK00
NOMESCO Finland
Perimetry
9.0
31.1
42
55
Q85.1
ICD-10 Finland
Tuberous sclerosis
+∞
30.9
29
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.3
25.9
33
40
Q85.9
ICD-10 Finland
Phakomatosis, unspecified
+∞
24.4
23
*
QCE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in upper limb
17.7
19.4
30
19
NDR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of wrist or hand
27.6
18.6
25
10
TQW99
NOMESCO Finland
Other minor procedure on skin
6.6
16.4
28
47
ACB19
NOMESCO Finland
Excision of lesion of peripheral nerve other or unspecified
51.1
16.3
19
*
D36.1
ICD-10 Finland
Benign neoplasm: Peripheral nerves and autonomic nervous system
90.8
15.8
17
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.9
15.1
36
83
ZXC10
NOMESCO Finland
Use of laser
12.5
14.7
26
23
R4120
NOMESCO Finland
Occupational therapy
4.7
14.4
36
86
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
19.6
13.6
20
11
D33.30
ICD-10 Finland
Acoustic neuroma
28.3
12.2
16
6
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
4.9
11.7
27
60
XCK10
NOMESCO Finland
Photography of fundus of eye
3.9
11.0
35
100
QDA25
NOMESCO Finland
Destruction of lesion of skin of lower limb
114.6
10.5
11
*
L81.3
ICD-10 Finland
Café au lait spots
+∞
10.5
10
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
24.6
10.4
14
6
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.2
10.3
46
165
NK1AT
NOMESCO Finland
Muscle biopsy with ultrasound guidance
57.2
9.7
11
*
D48.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Neoplasm of uncertain or unknown behaviour, unspecified
10.7
9.7
18
18
Q82.50
ICD-10 Finland
Naevus flammeus
103.8
9.5
10
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
9.1
9.0
18
21
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.4
8.8
34
111
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
8.7
81
420
ZXE10
NOMESCO Finland
More than one and less than three hours
2.3
8.6
98
553
9736
FHL
Subcutaneous tumor removal in operating room or anesthesia
20.9
8.6
12
6
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.7
8.5
20
45
ZXA00
NOMESCO Finland
Right side
2.5
8.5
67
322
QBA40
NOMESCO Finland
Laser therapy or photocoagulation of skin of trunk
93.0
8.5
9
*
ZXC07
NOMESCO Finland
Carbon dioxide laser
93.0
8.5
9
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
10.0
8.4
16
17
QXA40
NOMESCO Finland
Skin laser treatment or photocoagulation, unspecified location
+∞
8.4
8
*
XA800
NOMESCO Finland
Neuropsychological investigation
3.9
8.4
26
73
SPAT1229
SPAT
Assessment of need for aid
4.8
8.3
19
42
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.5
8.1
15
15
D37.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Small intestine
34.6
8.1
10
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.2
8.0
102
599
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
8.0
45
183
NFR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of hip or thigh
46.4
7.8
9
*
D33.45
ICD-10 Finland
Benign Schwannom in the nerve root of the spinal cord
46.4
7.8
9
*
D21.1
ICD-10 Finland
Benign neoplasm: Connective and other soft tissue of upper limb, including shoulder
19.1
7.7
11
6
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
9.3
7.7
15
17
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
9.3
7.7
15
17
D48.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Connective and other soft tissue
8.1
7.5
16
21
D33.46
ICD-10 Finland
Benign neurofibroma in the nerve root of the spinal cord
+∞
7.3
7
*
QAE40
NOMESCO Finland
Repair of anomaly or lesion after disease of skin of head or neck
+∞
7.3
7
*
C72.3
ICD-10 Finland
Malignant neoplasm: Optic nerve
+∞
7.3
7
*
WX1DG
NOMESCO Finland
Very extensive total body MRI with high intensity magnet
+∞
7.3
7
*
SPAT1153
SPAT
Removal of sutures
2.2
7.3
80
440
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
7.2
33
119
QA4S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in face
31.0
7.2
9
*
H47.2
ICD-10 Finland
Optic atrophy
31.0
7.2
9
*
WX002
NOMESCO Finland
Sedation and analgesia
2.5
7.2
51
232
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
9.2
7.1
14
16
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
7.3
7.1
16
23
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.6
7.0
44
189
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
7.5
6.8
15
21
QAA25
NOMESCO Finland
Destruction of lesion of head or neck
8.2
6.7
14
18
N03AF02
ATC
oxcarbazepine; oral
4.4
6.7
17
41
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
12.7
6.6
11
9
L28
ICPC
Limited function/disability (L)
2.5
6.6
45
200
D23.5
ICD-10 Finland
Benign neoplasm: Skin of trunk
6.0
6.6
17
30
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
7.7
6.5
14
19
ZXE20
NOMESCO Finland
More than three and less than five hours
2.6
6.5
40
170
QCA40
NOMESCO Finland
Laser therapy or photocoagulation of skin of upper limb
71.6
6.5
7
*
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
71.6
6.5
7
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.5
6.5
23
71
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
14.8
6.4
10
7
QCA25
NOMESCO Finland
Destruction of lesion of skin of upper limb
18.6
6.3
9
5
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
18.6
6.3
9
5
WX1CG
NOMESCO Finland
Extensive total body MRI with high intensity magnet
+∞
6.3
6
*
N03AX14
ATC
levetiracetam; systemic
5.8
6.1
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
18
20
9.60
9.19
3.6
2.8
2.16
2.86
nmol/l
0.36
18
20
48
194
2.82
8.62
7.6
13.4
-0.40
0.89
mmol/l
1.45
36
160
132
877
2.06
7.31
7.8
7.4
1.20
1.22
mmol/l
2.30
125
816
137
965
1.92
6.01
8.7
8.0
1.20
1.21
mmol/l
0.97
119
840
36
154
2.56
5.72
8.7
9.2
23.21
24.97
mmol/l
3.38
36
154
16
45
3.73
5.13
2.3
1.6
—
—
—
0
0
30
141
2.28
3.90
2.6
2.6
76.36
70.08
ml/min/173m2
0.32
11
63
7
8
8.96
3.79
4.9
3.9
60.29
228.37
nmol/l
—
7
8
25
114
2.32
3.48
11.7
14.5
0.54
0.66
%
0.79
25
114
49
289
1.86
3.48
2.1
2.2
29.05
29.43
s
0.28
49
282
20
414
0.44
3.24
1.4
1.3
0.99
5.83
u/ml
—
7
159
82
583
1.60
2.94
3.0
2.9
0.74
0.36
e6/l
0.32
70
407
28
144
2.06
2.94
3.8
4.3
108.70
74.54
ng/l
0.33
23
131
11
35
3.24
2.68
3.8
3.1
4.67
5.13
kpa
1.18
11
35
10
30
3.43
2.63
1.8
2.8
15.91
16.16
%
—
10
30
7
15
4.77
2.61
1.0
1.7
—
—
—
0
0
12
42
2.95
2.58
1.9
1.5
—
—
—
0
0
147
1709
0.67
2.53
3.2
3.6
—
—
—
0
0
19
89
2.23
2.52
1.4
1.3
—
—
—
0
0
9
28
3.29
2.33
1.1
1.0
—
—
—
0
0
80
593
1.51
2.32
4.1
3.6
0.00
0.01
estimate
0.80
26
221
6
13
4.70
2.28
1.5
1.1
—
—
—
0
0
16
73
2.27
2.26
5.8
5.5
1.24
1.29
mg/l
0.21
16
65
13
54
2.48
2.23
1.8
1.5
—
—
—
0
0
5
9
5.64
2.22
2.0
1.4
—
—
—
0
0
5
9
5.64
2.22
2.0
1.4
—
—
—
0
0
121
982
1.45
2.19
3.1
2.8
—
—
estimate
—
0
0
5
10
5.08
2.08
2.2
1.5
—
—
—
0
0
12
50
2.47
2.06
1.5
1.2
—
—
—
0
0
39
251
1.65
2.05
12.7
8.1
105.33
104.59
mmol/l
0.39
39
251
90
698
1.45
2.05
2.9
3.1
20.32
22.67
ng/l
0.20
58
418
13
57
2.35
2.01
1.9
2.3
25.70
24.51
mmol/l
0.45
13
57
68
504
1.48
1.94
2.2
2.4
—
—
—
0
0
7
22
3.24
1.89
1.6
1.8
0.50
0.58
e9/l
—
7
22
29
450
0.60
1.85
1.3
1.3
26.00
26.90
iu/ml
—
7
138
129
1085
1.39
1.80
7.3
6.5
10.80
12.00
umol/l
0.57
124
1037
29
444
0.61
1.75
2.0
2.2
—
—
—
0
0
32
473
0.63
1.66
2.1
2.3
—
—
—
0
0
81
639
1.39
1.63
2.9
2.6
55.30
62.40
u/l
0.40
76
603
22
129
1.77
1.63
1.7
1.6
—
—
—
0
0
5
14
3.62
1.62
1.6
1.5
—
—
—
0
0
8
32
2.55
1.61
1.9
1.4
—
—
—
0
0
8
32
2.55
1.61
1.9
1.6
—
—
—
0
0
10
43
2.38
1.60
1.7
1.6
—
—
—
0
0
30
196
1.60
1.51
5.3
4.1
1.68
1.92
mmol/l
0.16
23
164
84
676
1.36
1.48
3.2
3.4
2.35
2.36
mmol/l
0.33
76
630
102
846
1.34
1.48
5.3
5.0
35.34
36.87
g/l
1.72
95
807
28
182
1.61
1.45
4.4
3.3
—
—
—
0
0
35
240
1.53
1.45
1.8
1.8
—
—
—
0
0
45
326
1.46
1.44
2.8
2.7
4.66
2.33
e6/l
0.95
22
138
176
1590
1.35
1.39
8.2
7.7
76.65
77.73
u/l
0.10
168
1508
49
364
1.43
1.38
2.8
2.5
1.30
0.68
e6/l
0.40
25
174
132
1149
1.31
1.33
4.0
3.4
0.03
0.00
estimate
0.40
31
230
14
77
1.87
1.28
1.8
1.4
—
—
—
0
0
26
172
1.57
1.26
2.0
4.1
2.48
35.27
ug/l
0.68
18
134
22
331
0.63
1.24
1.9
1.9
3.66
3.52
ratio
0.32
14
258
6
26
2.34
1.19
1.7
1.5
—
—
—
0
0
132
1162
1.28
1.18
4.0
3.4
0.00
0.00
estimate
-0.00
29
233
29
201
1.50
1.16
7.0
6.2
—
—
—
0
0
16
253
0.61
1.12
1.6
1.8
3.63
3.49
mmol/l
—
8
179
132
1169
1.27
1.09
4.0
3.5
0.00
0.00
estimate
-0.00
31
218
42
317
1.39
1.09
1.9
2.0
—
—
—
0
0
19
122
1.60
1.06
3.5
6.0
1.80
1.26
mmol/l
0.26
12
97
32
232
1.43
1.04
1.8
1.9
—
—
—
0
0
12
68
1.80
1.02
1.8
1.5
—
—
—
0
0
12
68
1.80
1.02
1.2
1.4
515.67
445.37
mg/l
0.25
12
63
14
85
1.68
0.96
1.4
1.2
—
—
—
0
0
61
498
1.30
0.95
1.8
1.8
0.70
0.95
mg/l
0.55
46
391
7
37
1.92
0.95
1.7
1.2
313.86
367.85
mu/l
—
7
27
6
27
2.25
0.94
1.3
1.2
—
—
—
0
0
10
55
1.85
0.93
1.9
2.4
—
—
—
0
0
225
2153
1.41
0.92
20.8
14.7
139.27
139.72
mmol/l
1.78
220
2108
100
871
1.24
0.92
3.8
3.2
0.00
0.02
estimate
0.68
26
199
225
2155
1.40
0.89
20.7
14.8
3.94
3.94
mmol/l
0.06
220
2103
8
43
1.89
0.88
1.6
1.5
—
—
—
0
0
62
513
1.28
0.88
4.2
3.4
1.02
1.02
kg/l
0.46
38
327
11
64
1.75
0.87
1.8
1.5
—
—
—
0
0
13
80
1.66
0.86
1.2
1.1
—
5.73
—
0
12
0
27
0.00
0.78
0.0
1.1
—
—
—
0
0
21
150
1.44
0.76
2.3
2.2
0.42
0.15
e6/l
0.56
21
141
7
38
1.87
0.74
2.3
1.4
—
—
—
0
0
46
377
1.27
0.71
3.5
3.4
476.00
374.89
ng/l
0.09
28
248
189
1983
0.81
0.69
3.8
3.8
1.19
1.25
mmol/l
0.60
171
1868
5
29
1.74
0.64
1.2
1.3
—
—
—
0
0
5
30
1.68
0.61
1.4
1.6
—
—
—
0
0
139
1291
1.17
0.58
10.4
9.9
4.42
3.98
e9/l
1.39
121
1117
202
2096
0.82
0.58
4.4
4.4
1.48
1.46
mmol/l
0.28
186
1984
5
87
0.57
0.57
1.8
1.5
1.10
1.17
g/l
—
5
81
49
572
0.82
0.57
3.3
4.1
4.02
8.76
mg/mmol
1.24
36
359
25
195
1.31
0.57
3.1
4.0
209.44
236.43
u/l
0.81
25
188
6
37
1.64
0.56
2.8
2.9
17.93
6.39
pmol/l
—
6
37
6
37
1.64
0.56
1.2
1.1
—
—
—
0
0
9
60
1.52
0.55
1.1
1.5
—
—
—
0
0
107
979
1.16
0.53
2.6
2.6
73.17
74.16
nmol/l
0.15
101
906
6
39
1.55
0.53
1.7
3.1
11.33
37.79
u/ml
—
6
39
58
657
0.85
0.49
1.5
1.4
1.22
1.93
u/ml
0.37
18
173
8
118
0.67
0.47
2.8
2.0
—
—
—
0
0
40
341
1.21
0.45
4.6
3.9
26.48
21.64
%
1.59
23
135
206
2119
0.85
0.41
5.1
5.0
2.83
2.78
mmol/l
0.34
191
2007
0
15
0.00
0.41
0.0
1.1
—
9.80
—
0
15
0
16
0.00
0.41
0.0
1.0
—
1583.88
—
0
16
56
624
0.87
0.38
1.5
1.7
—
—
—
0
0
9
67
1.36
0.38
1.7
2.1
137.37
199.52
ug/l
—
9
59
14
180
0.76
0.38
1.9
1.3
141.93
118.66
u/ml
—
8
73
5
37
1.36
0.37
1.2
1.2
—
—
—
0
0
198
2037
0.87
0.36
5.9
5.1
1.82
1.83
mu/l
0.01
184
1919
205
2104
0.86
0.36
4.5
4.5
4.73
4.68
mmol/l
0.29
191
2003
12
156
0.76
0.35
1.1
1.1
—
—
—
0
0
41
360
1.17
0.35
1.7
1.7
368.03
445.26
pmol/l
1.92
30
322
6
44
1.37
0.34
2.0
1.4
—
—
—
0
0
6
46
1.31
0.33
1.5
1.9
—
—
—
0
0
18
146
1.25
0.33
1.8
1.4
—
—
—
0
0
240
2428
0.78
0.30
25.8
19.9
4.65
4.57
e12/l
1.34
233
2384
24
279
0.85
0.28
2.0
2.3
—
—
—
0
0
59
541
1.12
0.28
1.5
1.6
15.67
21.76
nmol/l
3.62
53
473
216
2199
0.88
0.26
16.4
13.3
26.32
22.45
mg/l
0.73
179
1714
240
2425
0.80
0.25
25.8
20.0
261.78
256.18
e9/l
0.72
233
2388
6
85
0.70
0.24
1.3
1.7
—
—
—
0
0
5
40
1.25
0.22
1.0
1.3
7.66
22.20
u/l
—
5
33
5
40
1.25
0.22
1.2
1.3
—
—
—
0
0
5
40
1.25
0.22
1.2
1.3
—
—
—
0
0
13
156
0.82
0.22
1.2
1.3
—
31.58
—
0
12
5
42
1.19
0.21
1.0
1.1
—
—
—
0
0
8
102
0.78
0.21
1.1
1.1
1.61
1.56
g/l
—
8
102
8
104
0.76
0.21
1.4
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
8.65
—
0
11
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
2.4
—
3.09
—
0
5
0
14
0.00
0.20
0.0
2.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
206.82
—
0
14
6
50
1.20
0.20
1.3
1.1
—
1.51
—
0
12
6
52
1.16
0.19
6.8
5.8
—
770.00
—
0
7
12
100
1.21
0.18
1.9
1.8
—
—
—
0
0
87
830
1.07
0.18
1.8
2.0
92.00
95.99
pmol/l
0.35
52
430
7
62
1.13
0.17
1.3
1.4
—
—
—
0
0
5
67
0.74
0.17
1.4
1.5
62.08
51.51
ug/l
—
5
67
12
101
1.20
0.17
6.9
2.8
0.50
0.64
%
2.14
12
101
16
140
1.15
0.15
3.3
1.5
0.35
0.29
mg/l
—
9
57
22
243
0.90
0.14
1.8
2.1
—
—
—
0
0
16
141
1.14
0.14
1.7
2.4
373.17
4333.41
u/l
—
6
54
18
161
1.13
0.13
1.4
1.5
—
—
—
0
0
228
2299
0.92
0.11
11.6
10.6
22.54
27.54
u/l
5.71
219
2247
163
1603
1.05
0.10
3.6
4.1
10.34
9.51
mm/h
0.29
152
1509
96
933
1.05
0.10
1.7
1.9
1.20
1.35
mmol/l
1.40
81
809
12
106
1.14
0.10
1.2
2.1
35.05
40.69
u/l
0.46
12
96
5
45
1.11
0.10
13.8
5.0
3.76
3.91
mmol/l
—
5
45
40
420
0.94
0.09
1.5
1.5
—
—
—
0
0
6
56
1.07
0.08
1.2
1.9
—
—
—
0
0
197
1949
1.05
0.08
4.4
5.3
35.67
38.07
mmol/mol
5.51
183
1863
6
75
0.80
0.07
2.8
1.9
—
—
—
0
0
8
74
1.08
0.07
1.0
1.1
—
16.86
—
0
12
9
87
1.04
0.07
1.4
1.5
—
—
—
0
0
68
662
1.04
0.06
2.7
2.8
0.00
0.01
estimate
0.50
25
190
9
105
0.85
0.06
1.2
1.1
0.76
0.90
g/l
—
9
105
28
267
1.05
0.05
1.9
1.6
1054.73
1179.39
nmol/l
0.34
22
202
231
2302
1.04
0.02
21.3
15.8
70.47
72.55
umol/l
0.33
231
2271
199
1999
0.98
0.02
4.2
4.3
5.51
5.76
mmol/l
4.69
183
1873
50
494
1.02
0.00
2.3
2.9
335.74
329.25
umol/l
0.12
43
446
25
248
1.01
0.00
3.2
2.6
0.85
0.66
ug/l
0.68
17
135
174
1742
1.00
0.00
5.1
4.2
14.89
14.63
pmol/l
0.75
163
1608
203
2033
0.99
0.00
17.0
12.0
95.10
89.99
ml/min/173m2
2.07
185
1835
22
216
1.02
0.00
3.1
4.2
33.47
31.83
%
0.30
17
143
6
67
0.89
-0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
99.33
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
54.17
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
66
0.91
-0.00
1.8
2.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
43.60
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
9.86
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.6
—
1.00
—
0
9
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
66
0.91
-0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
50.92
—
0
6
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: Q17_NEUROFIBROMATOSIS_1 – Neurofibromatosis, type 1
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).